The complete response letter was issued as a result of test results at a third-party manufacturing facility, unrelated to the efficacy or safety of patritumab deruxtecan in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer.
FDA Issues Complete Response to Merck and Daiichi Sankyo Regarding Patritumab Deruxtecan for Advanced Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Leave a comment
